These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 30325727)

  • 1. Underutilization of the current clinical capacity to provide buprenorphine treatment for opioid use disorders within the Veterans Health Administration.
    Valenstein-Mah H; Hagedorn H; Kay CL; Christopher ML; Gordon AJ
    Subst Abus; 2018; 39(3):286-288. PubMed ID: 30325727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
    Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H
    Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of DATA 2000 certification trainings for the provision of buprenorphine treatment in the Veterans Health Administration.
    Gordon AJ; Liberto J; Granda S; Salmon-Cox S; Andree T; McNicholas L
    Am J Addict; 2008; 17(6):459-62. PubMed ID: 19034736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advancing pharmacological treatments for opioid use disorder (ADaPT-OUD): protocol for testing a novel strategy to improve implementation of medication-assisted treatment for veterans with opioid use disorders in low-performing facilities.
    Hagedorn H; Kenny M; Gordon AJ; Ackland PE; Noorbaloochi S; Yu W; Harris AHS
    Addict Sci Clin Pract; 2018 Dec; 13(1):25. PubMed ID: 30545409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder.
    Jones CM; McCance-Katz EF
    Addiction; 2019 Mar; 114(3):471-482. PubMed ID: 30194876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implementation of buprenorphine in the Veterans Health Administration: results of the first 3 years.
    Gordon AJ; Trafton JA; Saxon AJ; Gifford AL; Goodman F; Calabrese VS; McNicholas L; Liberto J;
    Drug Alcohol Depend; 2007 Oct; 90(2-3):292-6. PubMed ID: 17493771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Barriers and Facilitators to Implementation of Pharmacotherapy for Opioid Use Disorders in VHA Residential Treatment Programs.
    Finlay AK; Wong JJ; Ellerbe LS; Rubinsky A; Gupta S; Bowe TR; Schmidt EM; Timko C; Burden JL; Harris AHS
    J Stud Alcohol Drugs; 2018 Nov; 79(6):909-917. PubMed ID: 30573022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-acting intramuscular naltrexone for opioid use disorder: Utilization and association with multi-morbidity nationally in the Veterans Health Administration.
    Kelly MM; Reilly E; Quiñones T; Desai N; Rosenheck R
    Drug Alcohol Depend; 2018 Feb; 183():111-117. PubMed ID: 29245103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-year retention in buprenorphine treatment for opioid use disorder nationally in the Veterans Health Administration.
    Manhapra A; Petrakis I; Rosenheck R
    Am J Addict; 2017 Sep; 26(6):572-580. PubMed ID: 28472543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prescribing Practices of Nurse Practitioners and Physician Assistants Waivered to Prescribe Buprenorphine and the Barriers They Experience Prescribing Buprenorphine.
    Andrilla CHA; Jones KC; Patterson DG
    J Rural Health; 2020 Mar; 36(2):187-195. PubMed ID: 31650634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.
    Lin LA; Bohnert ASB; Blow FC; Gordon AJ; Ignacio RV; Kim HM; Ilgen MA
    Addiction; 2021 Jan; 116(1):96-104. PubMed ID: 32428386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming Barriers to Prescribing Buprenorphine for the Treatment of Opioid Use Disorder: Recommendations from Rural Physicians.
    Andrilla CHA; Moore TE; Patterson DG
    J Rural Health; 2019 Jan; 35(1):113-121. PubMed ID: 30339720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buprenorphine Prescribing and Challenges Faced Among National Health Service Corps Clinicians.
    Rowan K; Shah SV; Binns S; Murphy E; Satorius J; Ghobadi A; Krauss D; Robbins C; Schoebel V; Knudson A; Kepley H;
    JAMA Netw Open; 2024 May; 7(5):e2411742. PubMed ID: 38758556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empowering Psychiatric Mental Health Nurse Practitioners to Expand Treatment Opportunities for Veterans With Opioid Use Disorder.
    Jones J; Tierney M; Jacobs G; Chien SY; Mallisham S
    J Addict Nurs; 2020; 31(4):261-268. PubMed ID: 33264198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Receipt of opioid agonist treatment in the Veterans Health Administration: facility and patient factors.
    Oliva EM; Harris AH; Trafton JA; Gordon AJ
    Drug Alcohol Depend; 2012 May; 122(3):241-6. PubMed ID: 22115887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans.
    Petrakis I; Springer SA; Davis C; Ralevski E; Gu L; Lew R; Hermos J; Nuite M; Gordon AJ; Kosten TR; Nunes EV; Rosenheck R; Saxon AJ; Swift R; Goldberg A; Ringer R; Ferguson R
    Addict Sci Clin Pract; 2022 Jan; 17(1):6. PubMed ID: 35101115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to coronavirus 2019 in Veterans Health Administration facilities participating in an implementation initiative to enhance access to medication for opioid use disorder.
    Gustavson AM; Gordon AJ; Kenny ME; McHenry H; Gronek J; Ackland PE; Hagedorn HJ
    Subst Abus; 2020; 41(4):413-418. PubMed ID: 32936695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Barriers to primary care physicians prescribing buprenorphine.
    Hutchinson E; Catlin M; Andrilla CH; Baldwin LM; Rosenblatt RA
    Ann Fam Med; 2014; 12(2):128-33. PubMed ID: 24615308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Datapoints: regional variation in benzodiazepine prescribing for patients on opioid agonist therapy.
    Park TW; Bohnert AS; Austin KL; Saitz R; Pizer SD
    Psychiatr Serv; 2014 Jan; 65(1):4. PubMed ID: 24382761
    [No Abstract]   [Full Text] [Related]  

  • 20. Office-based management of opioid dependence with buprenorphine: clinical practices and barriers.
    Walley AY; Alperen JK; Cheng DM; Botticelli M; Castro-Donlan C; Samet JH; Alford DP
    J Gen Intern Med; 2008 Sep; 23(9):1393-8. PubMed ID: 18592319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.